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Abstract
The isodecyl neopentanoate is an ingredient used in the cosmetic industry toprepare a nipple fissure balm.Wereport on12newborns
that showed elevated C5-acylcarnitine levels upon newborn screening following treatment with balm. The first 3 neonates were
immediately recalled for confirmatory tests and resulted negative for both isovaleric acidemia and short/branched chain acyl-CoA
dehydrogenase deficiency. In the other 9 cases, the immediate recall was avoided by applying a new second-tier test able to confirm
the presence of pivaloylcarnitine. The concentration of C5-acylcarnitine was measured in the days following the suspension of
balm application. Abnormal concentrations of C5-acylcarnitine did not seem to be associated with free carnitine deficiency,
probably due to the short time of exposure. A direct correlation between balm ingestion and the elevation in pivaloylcarnitine
has been demonstrated in 10 adult volunteers. The commercial balm containing a pivalic acid derivative is causal of false-positive
results during newborn screening, and it could have the potential to cause secondary carnitine deficiency when used chronically.
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Introduction
Acylcarnitine profile analysis using the flow injection analy-
sis–tandem mass spectrometry (MS/MS) method is commonly
used in newborn screening programs for the biochemical
screening of fatty acid oxidation and organic acid metabolism
disorders.
The profile is analyzed in positive-ion mode, usually using a
precursor ion scan experiment or a multiple reaction monitor-
ing (MRM) experiment. A common fragment (85 m/z) contain-
ing the quaternary ammonium function could be detected with
high sensitivity and specificity. Flow injection analysis–MS/
MS methods cannot distinguish between isobaric compounds,
making chromatographic separation essential when the separa-
tion of isomers is required for the differential diagnosis of some
inborn errors of metabolism.1,2
Several authors have developed methods for the determina-
tion of C4-acylcarnitine and C5-acylcarnitine isomers in
plasma and dried blood spots (DBSs) by ultra-performance
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liquid chromatography (LC)–MS/MS as a second-tier test fol-
lowing flow injection–MS/MS acylcarnitine profile analysis.3
In particular, an increase in C5-acylcarnitine in a newborn
screening profile indicates a possible isovaleric acidemia
(IVA) with elevated isovalerylcarnitine (IC) or a possible
short/branched chain acyl-CoA dehydrogenase deficiency
(SBCADD) with elevated 2-methylbutyrylcarnitine
(2MBC).
Table 1. Free Carnitine and C5-Acylcarnitine Concentrations Detected During Expanded Newborn Screening Program in 12 Infants Whose
Mothers Used the Nipple Fissure Balm.
Case













1a 1.18 3.63 0.29 (7) 24.4 24.1 26.9 (7)
2a 0.82 0.85 0.11 (10) 13.02 12.02 23.6 (10)
3a 1.13 1.32 0.30 (4) 20.38 18.11 29.5 (4)
4 0.86 - 0.44 (3) 22.33 - 29.4 (3)
5 0.62 - 0.22 (2) 25.62 - 26.7 (2)
6 0.91 - 0.64 (3) 20.74 - 29.1 (3)
7 1.02 - 0.34 (4) 22.9 - 21.2 (4)
8 0.66 - 0.19 (4) 31.9 - 31.6 (4)
9 0.89 - 0.22 (2) 33.37 - 26.5 (2)
10 0.73 - 0.15 (10) 20.51 - 20.5 (10)
11 1.8 - 0.29 (5) 29 - 27.5 (5)
12 1.1 - 0.17 (4) 10.7 15.0 (4)
Abbreviation: nv, normal value.
aNewborns immediately recalled for clinical evaluation.
Figure 1. Chromatographic separation of the selected transition 302! 85.0 m/z. The chromatogram corresponds to a solution spiked with
0.05 μmol/L of pivaloylcarnitine, 0.1 μmol/L of 2-methylbutyrylcarnitine, and 0.1 μmol/L of isovalerylcarnitine in the presence of D9-isovaler-
ylcarnitine (311 ! 85.0 m/z). The separate peaks show enough chromatographic resolution of C5-acylcarnitine isomers.
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Moreover, an increase in C5-acylcarnitine due to the pres-
ence of pivaloylcarnitine (PC) originating from pivalic acid in
some antibiotic preparations and generating many false-
positive results in newborn screening programs has been
reported in the literature.4,5 More recently, Boemer and colla-
borators described a pivalic acid derivative ‘‘neopentanoate’’
used in the cosmetic industry to formulate a nipple fissure
unguent that leads to false-positive increases in C5-acylcarni-
tine.6 In 2015, Yamada and colleagues reported on 2 cases that
developed elevated C5-acylcarnitine levels following treat-
ment with sivelestat, a neutrophil elastase inhibitor used to treat
acute respiratory distress syndrome.7
Patients with SBCADD are generally asymptomatic, and its
clinical consequences are not yet known.8,9 On the contrary,
IVA is a branched-chain amino acid metabolism disorder char-
acterized by severe episodes of ketoacidosis, vomiting, and
lethargy, progressing to coma.10
It is therefore very important to differentiate between IVA,
SBCADD, and increased levels of C5 due to PC. In 2014, an
increased false-positivity rate due to elevated C5-acylcarnitine
was observed in the newborn screening programs of Tuscany
and Northern Sicily.
Here, we report 12 cases presenting elevated C5-
acylcarnitine due to nipple fissure balm, and we describe the
second-tier method developed to identify specific isobars on
DBS from newborns. Moreover, a direct correlation between
the ingestion of nipple fissure balm and growing values of C5-
carnitine has been demonstrated in 10 adult volunteers.
Materials and Methods
Standards and Solvents
D9-isovalerylcarnitine (D9-IC) was purchased from Cambridge
Isotope Laboratories (Andover, Massachusetts) to be used as an
internal standard. The PC, 2MBC, and IC standard solutions
were a gift from the Department of Chemistry of the University
of Florence. Stock solutions of chemical and labeled standards
at 100 mmol/L were prepared in methanol and stored at20C.
Other reagents such as LC/MS-grade water, formic acid (purity
Figure 2. Extracted ion chromatogram of the monitored mass transitions 302!85 m/z and 311!85 m/z (used as internal standard) in a normal
newborn (A), in a patient with isovaleric acidemia (IVA; B), in a patient with short-branched chain acyl-CoA dehydrogenase deficiency
(SBCADD; C), and in a breast-fed neonate whose mother was using nipple cream (D).
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98%-100%), and LC/MS grade acetonitrile were purchased
from Panreac (Barcelona, Spain). N-butanol containing 3N
HCl, used as a derivatizing agent for the second-tier test, was
purchased from Regis Chemical (Morton Grove, Illinois).
Sample Preparation and Chromatography
For the sample extraction, 200 μL of methanol solution con-
taining D9-IC as an internal standard at a concentration of 40
nmol/L was added to a DBS punch (3.2-mm diameter, about
3.3-3.5 μL) and kept at 37C for 25 minutes in an orbital
shaker. The extracted samples were completely dried under
nitrogen flow at room temperature (Evaporator Porvair
Micro-DS 96; Stepbio, Bologna, Italy) and were then deriva-
tized using 75 μL of 3N HCl in n-butanol and kept at 65C for
20 minutes. The derivatized samples were completely dried
under nitrogen flow at 40C and finally reconstituted with
200 μL of water/acetonitrile 30:70 (vol/vol) þ 0.1% of formic
acid to prepare them for analysis.
The chromatographic separations were performed on an
Agilent 1260 Quaternary Capillary Pump with a Synergi
Polar-RP 80A, 4 μm 150  2 mm high-performance liquid
chromatography column (Phenomenex, Anzola, Bologna,
Italy) and 4  2 mm precolumn cartridge (Phenomenex) for
separation.
The mobile phase was composed of water (eluent A) and
methanol (eluent B) with a flow rate of 200 μL/min. Gradient
elution was achieved using a program with mobile phase A and
mobile phase B as follows: 5% B to 50% B in 3 minutes and
maintained for 0.1 minute, then from 50% B to 80% in 0.1
minute and maintained for 4.5 minutes, then back to 5% B in
0.1 minute and reequilibration for 4.2 minutes. The total anal-
ysis run time was 12 minutes. One microliter of the extracted
sample was injected for the LC–MS/MS experiments.
An API 4000 Triple-Quad Mass Spectrometer equipped
with the Turbo V-spray source with the turbo gas temperature
set at 400C was used for the MS/MS tests. The source operates
in positive ionization polarity at a potential of þ5500 V. The
transitions for the MRM experiments were 302.2! 85 m/z for
C5 isomers and 311.2 ! 85 m/z for the labeled internal stan-
dard D9-IC. Optimal Collision Energy (CE), Cell exit Potential
(CXP) and Declustering Potential (DP) were found at 25, 7, and
40 V, respectively, for both transitions.
Experimental Design and Sample Collection
About 300 mg of a nipple fissure balm containing neopentano-
ate as a cosmetic ingredient was added to 50 mL of commercial
fresh pasteurized cow milk and administered to 3 males and 5
females, all volunteers from the NBS laboratory of Meyer
Children’s Hospital.
Additionally, 2 volunteers, 1 male and 1 female, drank only
50 mL of commercial fresh pasteurized cow milk (vehicle)
without balm. Dried blood spot samples from each volunteer
were obtained by finger prick before and after balm ingestion
(T0, T1, T2, T4, T8, T24 hours). A fully automated finger
incision device for blood sampling was used (Tenderfoot Pre-
emie; ITC, Edison, New Jersey). Dried blood spots were pre-
pared by spotting whole blood onto filter paper cards (903;
Whatman GmbH, Dassel, Germany), which were then left to
dry and stored at 20C in a sealed plastic bag containing
desiccant until analysis. Samples were prepared in triplicate
for routine screening tests, as previously described.11
Results
Between January and December 2014, the newborn screening
programs of Tuscany (n ¼ 37111) and Northern Sicily (n ¼
16020), limited to LC–MS/MS testing, had a detection rate of
1:2062 and 1:2620, respectively. Of 91 total recalls in Tuscany,
5 (5.5%) were for abnormal values of isolated C5-acylcarnitine
(normal values 0.56 μmol/L). Of 529 total recalls in Sicily,
27 (5.1%) were for abnormal values of isolated C5 (normal
values  0.56 μmol/L). Only 2 of the 32 were true IVA posi-
tives—1 from Tuscany and 1 from Sicily.
Twelve of the 32 neonates showed abnormal C5-
acylcarnitine concentrations due to indirect absorption of iso-
decyl neopentanoate originating from a nipple fissure balm
used by nursing mothers to prevent rhagades. Three of them
were from the Tuscany Newborn Screening Center and 9 were
from the Northern Sicily Newborn Screening Center. The
remaining 18 false positives from newborn screening resulted
negative upon the second-tier test. The C5-acylcarnitine and
free carnitine concentrations of the 12 false-positive newborns
for balm are reported in Table 1.
As IVA can lead to acute metabolic decompensation, in the
period preceding the setup of the second-tier test, newborns 1
Figure 3. Graphic representation of the effect of balm ingestion on
blood C5-carnitine levels. Blood samples were collected sequentially
over a 24-hour period from 10 healthy volunteers, 8 who received an
oral dose of nursing balm (purple line) and 2 monitored as controls
(red line). The horizontal dashed line represents the higher cutoff of
C5 (0.35 μmol/L) on blood for normal adults.
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(from Tuscany), 2, and 3 (from Sicily) were immediately
recalled following the newborn screening results for clinical
evaluation and second-level confirmatory testing according to
internal protocol. However, IVA was considered to be unlikely
because isovalerylglycine and 3-OH-isovaleric acid were not
detected by urinary organic acid analysis. Moreover, no abnor-
mal findings such as body smell or hypoglycemia, which are
typical symptoms of IVA, were noted in these patients. During
the anamnestic evaluation, their mothers referred to the use of
the same nipple fissure balm (to prevent rhagades) at the time
that blood was drawn (as preventive of rhagades) without con-
comitant drug supplementation. After these first 3 cases, we
decided to develop a second-tier test able to separate C5-
acylcarnitine isomers.
Figure 1 shows the chromatographic separation of butylated
C5 isomers at 0.05 μmol/L (D9-IC and PC) and at 0.1 μmol/L
(2MBC and IC) in acetonitrile/water 70:30þ 0.1% formic acid.
The corresponding retention times were 7.83, 6.74, 7.50, and
7.87 minutes, respectively.
To assess whether second-tier testing could be effective, we
applied it to 100 blood spots reported as normal during new-
born screening by LC–MS/MS, and 32 spots recalled for abnor-
mal values of C5 (newborns 1, 2, and 3 were retrospectively
analyzed). In addition, we tested 4 truly positive newborn
screening blood spots (2 IVA and 2 SBCADD). No quantifiable
signal corresponding to IC or 2MBC was detected for controls
or false positives. Figure 2 shows the extracted ion chromato-
gram from a normal neonatal DBS (panel A), patient with IVA
(panel B), patient with SBCADD (panel C), and false positive
due to PC (panel D).
In the period of April to December 2014, the application of
the second-tier test allowed the identification of 9 additional
cases of false positives due to balm application during breast-
feeding. For all of them, we decided to ask for a new DBS after
the suspension of balm application to control the C5-
acylcarnitine normalization (Table 1).
A new experiment was performed in 10 adult volunteers to
demonstrate the direct correlation between balm ingestion and
the increase in C5-acylcarnitine blood levels. Eight of them (3
males and 5 females, age 25-46 years) received 50 mL of
commercially available fresh cow milk containing about 300
mg of the balm. One male (42 years old) and 1 female (46 years
old) drank only 50 mL of commercially available fresh cow
milk (vehicle) without balm. Dried blood spot samples were
obtained from each volunteer by finger prick over 24 hours.
Figure 3 shows the C5-acylcarnitine trend. The reported
C5 acylcarnitine values are the average of 3 replicates
for all volunteers at each time point. The maximum
C5-acylcarnitine blood concentration was reached 4 hours
after balm ingestion in all volunteers.
Figure 4. Flow diagram for the C5-carnitine evaluation in the newborn screening.
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Considering that the pivalic acid derivative neopentanoic acid
conjugates the free carnitine4-6 and that the breast-feeding period
could be quite long (generally somemonths),we cannot exclude a
potentially dangerous secondary carnitine deficiency due to a
long-term nipple fissure balm application. Exogenous unusual
long-term pivalate exposure from pivalic esters of antibiotics to
mothers or newborns had previously been reported as responsible
for carnitine depletion and hypoglycemic convulsions.12
Moreover, Ito and collaborators reported that serum-free
and total carnitine levels decreased by about 50% even after
short-term administration of these drugs.4 In our experience,
the free carnitine levels in the 12 false-positive newborns and in
adult volunteers were within the normal ranges (Table 1 and
Figure 3), probably due to short-term exposure.
The NBS protocol has been modified in daily practice as
reported in Figure 4. If an abnormal value of C5-acylcarnitine
is present during a routine newborn screening procedure, the
second-tier test is immediately performed. If PC is present, we
contact the mother by phone and ask if she has been using some
antibiotics or the balm. In the first case, no further action is
required if a short-term therapy has been recommended by a
physician; in the latter, we recommend the suspension of balm
application and/or possibly replacement with other creams. If
IC is present and the concentration in blood is higher than 0.56
μmol/L, we proceed to the immediate recall of the baby for
clinical evaluation and second-level confirmatory testing.
Considering that patients with SBCADD are generally
asymptomatic,8,9 SBCADD is not included in the NBS panel
because of its unknown clinical significance; therefore, if
2MBC is present, the newborn is not recalled.
Conclusion
The aim of this work is to declare that the use of the nipple fissure
cream containing neopentanoate esters as an ingredient causes
false-positive results during newborn screening. Warning nur-
series, pediatric facilities, and manufacturing companies about
the effects of these compounds is very important in order to
decrease diagnostic errors and consequent recalls. Recalls induce
stress in the families of newborns and may also cause the loss of
milk in mothers or influence the child-parent relationship.13
In the experiences of Tuscany and Sicily, the biomarker C5-
acylcarnitine is not causative of many recalls during newborn
screening (about 5%-6% of total recalls); however, the positive
predictive value of the biomarker is not good (2 IVA of the 32
positives corresponding to 6.25%). Based on the conviction
that the combination of first- and second-tier testing for many
metabolic disorders must be considered the best working
practice to achieve the most benefit out of newborn screening
programs, in our opinion, the new second-tier test for
C5-acylcarnitine can reduce the false-positive rate, improve
the positive predictive value, and above all avoid superfluous
urgent recalls with a consequent reduction in laboratory anal-
yses, personnel costs for repeat tests, and considerable anxiety
for parents. The use of pivalic acid derivatives in drugs or
cosmetics is still widespread worldwide, in spite of important
reports. During the preparation of this article, a new false
positive for C5-acylcarnitine was identified by the Tuscan
newborn screening program because of a newborn’s exposure
to an antibiotic named ‘‘cefditoren pivoxil,’’ a semisynthetic
cephalosporin used in pediatric patients with laryngopharyn-
gitis and tonsillitis. New and better strategies should be
developed to provide testing options that, applied to newborn
screening programs, reduce recall rate, overall expenses, and
parental anxiety.
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